Novel HDL-directed pharmacotherapeutic strategies

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Atherothrombotic cardiovascular disease poses a significant health burden, with residual risk persisting despite optimal medical therapy.
• High-density lipoprotein (HDL) possesses crucial atheroprotective functions, including reverse cholesterol transport, anti-inflammatory, antithrombotic, and antioxidant activities.
• Recent advancements have elucidated HDL's complex metabolic and antiatherosclerotic pathways.

Purpose of the Study:

• To explore novel therapeutic strategies targeting HDL to mitigate residual risk in cardiovascular disease.
• To review current HDL-targeted drug development approaches.

Main Methods:

• Review of recent scientific literature on HDL metabolism and function.
• Classification of HDL-targeted therapies into distinct categories.
• Discussion of specific therapeutic interventions within each category.

Main Results:

• Four primary therapeutic approaches for HDL-targeted drugs have been identified.
• These approaches include direct augmentation of apolipoprotein A-I (apo A-I) levels, indirect augmentation of apo A-I and HDL-cholesterol, mimicking apo A-I functionality, and enhancing reverse cholesterol transport.
• Specific examples include apo A-I infusions, cholesteryl ester transfer protein inhibition, apo A-I mimetic peptides, and liver X receptor activation.

Conclusions:

• HDL-targeted therapies represent a promising avenue for addressing residual risk in atherothrombotic cardiovascular disease.
• Further research and development in these areas hold potential for improved cardiovascular outcomes.